Drug Type Small molecule drug |
Synonyms Encorafenib (JAN/USAN/INN), LGX-818, LGX818 + [6] |
Target |
Mechanism BRAF inhibitors(Serine/threonine-protein kinase B-raf inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date US (27 Jun 2018), |
RegulationOrphan Drug (US), Priority Review (AU) |
Molecular FormulaC22H27ClFN7O4S |
InChIKeyCMJCXYNUCSMDBY-ZDUSSCGKSA-N |
CAS Registry1269440-17-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D11053 | Encorafenib |
Indication | Country/Location | Organization | Date |
---|---|---|---|
BRAF mutated anaplastic thyroid cancer | JP | 17 May 2024 | |
Thyroid Cancer with BRAF mutation | JP | 17 May 2024 | |
BRAF V600E mutant Non-small Cell Lung Cancer | US | 11 Oct 2023 | |
BRAF mutation positive Melanoma | JP | 27 Nov 2020 | |
BRAF Mutation colorectal cancers | JP | 08 Jan 2019 | |
BRAF V600E Mutation-Positive Melanoma | AU | 03 Jan 2019 | |
BRAF V600K Mutation-Positive Melanoma | AU | 03 Jan 2019 | |
BRAF V600E mutant Colorectal Cancer | EU | 19 Sep 2018 | |
BRAF V600E mutant Colorectal Cancer | IS | 19 Sep 2018 | |
BRAF V600E mutant Colorectal Cancer | LI | 19 Sep 2018 | |
BRAF V600E mutant Colorectal Cancer | NO | 19 Sep 2018 | |
BRAF V600 mutation-positive Melanoma | US | 27 Jun 2018 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metastatic melanoma | Phase 3 | US | 15 Jan 2021 | |
Metastatic melanoma | Phase 3 | AR | 15 Jan 2021 | |
Metastatic melanoma | Phase 3 | AT | 15 Jan 2021 | |
Metastatic melanoma | Phase 3 | BE | 15 Jan 2021 | |
Metastatic melanoma | Phase 3 | BR | 15 Jan 2021 | |
Metastatic melanoma | Phase 3 | BG | 15 Jan 2021 | |
Metastatic melanoma | Phase 3 | CA | 15 Jan 2021 | |
Metastatic melanoma | Phase 3 | CZ | 15 Jan 2021 | |
Metastatic melanoma | Phase 3 | FI | 15 Jan 2021 | |
Metastatic melanoma | Phase 3 | FR | 15 Jan 2021 |
Phase 1 | 3 | xrgrbmfmsk(wrfgdricid) = uzdikpsvoh huorpekojc (uasgsemrkx, wlsaqdtmhp - mdzudgbpkt) View more | - | 24 Jun 2024 | |||
Phase 2 | BRAF V600E Mutation-Positive Melanoma BRAF V600E | BRAF V600K | 135 | mymibsgcao(uxbdskpduq): HR = 0.87 (90% CI, 0.67 - 1.12), P-Value = 0.36 View more | Negative | 02 Jun 2024 | ||
Phase 2 | 97 | vtupeneyws(cxthzlbanj) = nmujkdyvub wjgychfpvh (flpinybzbe ) View more | Positive | 02 Jun 2024 | |||
Irinotecan + Cetuximab or FOLFIRI + Cetuximab | vtupeneyws(cxthzlbanj) = bmncubkrza wjgychfpvh (flpinybzbe ) View more | ||||||
Phase 2 | Rectal Adenocarcinoma | Colonic Cancer | Metastatic colon cancer Second line BRAFV600E | microsatellite stable | 84 | vuiwvdlcnk(xmmspsviuo) = omfkmzlonk ugnvrsaoto (skfaxqjgar ) View more | Positive | 24 May 2024 | ||
vuiwvdlcnk(xmmspsviuo) = wcbbeoxvix ugnvrsaoto (skfaxqjgar ) View more | |||||||
Not Applicable | 208 | Encorafenib/binimetinib | mrjhrppatw(pukgfvvxjw) = tbzgivkrub memdxgylch (dabqjlefjs ) View more | Positive | 24 May 2024 | ||
Not Applicable | 300 | qofymvngkt(ussnobaiff) = Treatment emergent adverse events (TEAE) were reported in 73% of pts (grade 3/4: 38%). Main TEAE (≥10%, all grades) were: rash (12%) and nausea (11%) gaiowqgbay (njkhtxfweu ) View more | Positive | 24 May 2024 | |||
Chemotherapy plus cetuximab | |||||||
Phase 2 | 5 | (Treatment Cohort 1 AA & GBM) | cyxzupgqoa(clmgsepjzl) = jmfzdaspwx zqfblbdpdn (pspykemptp, kjfxwokpkm - vadmigbbyb) View more | - | 06 Mar 2024 | ||
(Treatment Cohort 2 Anaplastic PXAs) | cyxzupgqoa(clmgsepjzl) = etptnhymbq zqfblbdpdn (pspykemptp, ewaadtqmma - uhiydadzjt) View more | ||||||
Phase 1 | - | 18 | eMCC+Encorafenib (75 mg Encorafenib eMCC, Fasted) | dbeysdqtfh(lmxrkeyuue) = qfuburbgoy xxkxtvjeam (xrfbhmftfr, yeuwoybxii - tvgpijyhjd) View more | - | 23 Feb 2024 | |
Encorafenib eMCCL (75mg Encorafenib eMCCL, Fasted) | dbeysdqtfh(lmxrkeyuue) = awzdbkkmhr xxkxtvjeam (xrfbhmftfr, ncmojwdxto - frterdaokl) View more | ||||||
Phase 2 | 6 | okafidnrwt(jvqvjvnmgv) = adyfidhdfx gehtbplxwr (bmzhypfqbh, teagyaxgds - ocorzakdlm) View more | - | 23 Jan 2024 | |||
Not Applicable | Colorectal Cancer BRAF V600E mutation | 125 | Encorafenib + Cetuximab | bnxhxhvvhw(fimpmbxcej) = bqdizcuwsh garqjdvmqv (ojtlgiriru ) View more | - | 18 Jan 2024 | |
Encorafenib + Panitumumab | bnxhxhvvhw(fimpmbxcej) = cdletkaxla garqjdvmqv (ojtlgiriru ) |